Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov:93:107-109.
doi: 10.1016/j.ejim.2021.09.012. Epub 2021 Sep 24.

Serum IgG4 level predicts COVID-19 related mortality

Emanuel Della-Torre  1 , Marco Lanzillotta  2 , Marta Strollo  3 , Giuseppe Alvise Ramirez  2 , Lorenzo Dagna  2 , Moreno Tresoldi  4 ; COVID-BioB study group
Affiliations

Serum IgG4 level predicts COVID-19 related mortality

Emanuel Della-Torre et al. Eur J Intern Med. 2021 Nov.
No abstract available

Keywords: COVID-19; IgG4; SARS-CoV-2; immunoglobulins; subclasses.

PubMed Disclaimer

Conflict of interest statement

The authors have not received any financial support or other benefits from commercial sources for the work reported in the manuscript, or any other financial interests that could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work.

Figures

Fig. 1
Fig. 1
Serum IgG4 level predicts COVID-19 related mortality. (A) Serum IgG4 concentration, but not IgG1, IgG2, and IgG3, is significantly higher in COVID-19 non-survivors compared to survivors (p value < 0.05). (B) Increased serum IgG4 level (> 700 mg/L) and IgG4/IgG1 ratio (> 0.05) are associated with increased mortality in COVID-19 patients (p value < 0.05 for both survival analyses). (C) Serum IgG4 concentration positively correlates with serum IL-6 levels (p value < 0.05).
See this image and copyright information in PMC

Comment in

  • Disguised aspects of IgG4.
    Dułak NA, Trzciński R. Dułak NA, et al. Eur J Intern Med. 2022 Jan;95:97. doi: 10.1016/j.ejim.2021.10.016. Epub 2021 Oct 27. Eur J Intern Med. 2022. PMID: 34756504 Free PMC article. No abstract available.

References

    1. Bastard P, Rosen LB, Zhang Q. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. - PMC - PubMed
    1. Giamarellos-Bourboulis EJ, Netea MG, Rovina N. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992–1000. .e3. - PMC - PubMed
    1. Chakraborty S, Gonzalez J, Edwards K. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2020;22:67–73. - PMC - PubMed
    1. Yates JL, Ehrbar DJ, Hunt DT. Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Rep Med. 2021;2 - PMC - PubMed
    1. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21:382–393. - PMC - PubMed

Substances